Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis

References

• Cox PA, Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS/PDC disease in Guam. Neurology. 2002; 58:956–9.
   PubMed Web of Science ®Google Scholar
• Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA. 2003; 100:13380–3.
   PubMed Web of Science ®Google Scholar
• Banack SA, Cox PA. Biomagnification of cycad neurotoxins in flying foxes: implications for ALS/PDC in Guam. Neurology. 2003; 61:387–9.
   PubMed Web of Science ®Google Scholar
• Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW. Occurrence of β-methylamino-L-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004; 110:267–9.
   PubMed Web of Science ®Google Scholar
• Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proceedings of the National Academy of Sciences. 2004; 101:12228–31.
   PubMed Web of Science ®Google Scholar
• Banack SA, Murch SJ, Cox PA. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J Ethnopharmacol. 2006; 106:97–104.
   PubMed Web of Science ®Google Scholar
• Banack SA, Johnson HE, Cheng R, Cox PA. Production of the neurotoxin BMAA by a marine cyanobacterium. Mar Drugs. 2007; 5:180–96.
   PubMed Web of Science ®Google Scholar
• Banak SA, Cox PA, Murch SJ. Flying fox consumption and human neurodegenerative disease in Guam. In: Fleming T, Racey P. Island Bats: Ecology Evolution, and Conservation. Chicago: The University of Chicago Press; 2009. (in press).
   Google Scholar
• Papapetropoulos S. Is there a role for naturally occurring cyanobacterial toxins in neurodegeneration? The beta-N-methylamino-L-alanine (BMAA) paradigm. Neurochem Int. 2007; 50:998–1003.
   PubMed Web of Science ®Google Scholar
• Karamyan VT, Speth RC. Animal models of BMAA neurotoxicity: a critical review. Life Sci. 2008; 82:233–46.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Banack SA, Cox PA, Bradley WG. 2007, Unpublished observations. . ; : –.
   Google Scholar
• Mash D, Pablo J, Banack SA, . Neurotoxic non-protein amino acid BMAA in brain from patients dying with ALS and Alzheimer's disease. American Academy of Neurology annual meeting. Neurology. 2008; 70Suppl 1:329–
   Google Scholar
• Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, . Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand. 2009; : –. DOI: 10.1111/j.1600-0404.2008.01150.x.
   PubMed Web of Science ®Google Scholar
• Hoogenraad TU. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice. Brain and Devel. 2005; 28:141–6.
   Web of Science ®Google Scholar
• Jakubowski H. Amino acid selectivity in the aminoacylation of coenzyme A and RNA minihelices by aminoacyl-tRNA synthetases. J Biol Chem. 2000; 275:34845–8.
   PubMed Web of Science ®Google Scholar
• Jakubowski H. Translational incorporation of S-nitrosohomocysteine into protein. J Biol Chem. 2000; 275:21813–6.
   PubMed Web of Science ®Google Scholar
• Muranaka N, Miura M, Taira H, Hohsaka T. Incorporation of unnatural non-alpha-amino acids into the N-terminus of proteins in a cell-free translation system. J Chemobiochem. 2007; 8:1650–3.
   PubMed Web of Science ®Google Scholar
• Goerke AR, Swartz JR. High-level cell-free synthesis yields of proteins containing site-specific non-natural amino acids. Biotechnol Bioeng. 2009; 102:400–16.
   PubMed Web of Science ®Google Scholar
• Hartman MC, Josephson K, Szostak JW. Enzymatic aminoacylation of tRNA with unnatural amino acids. Proc Natl Acad Sci USA. 2006; 103:4356–61.
   PubMed Web of Science ®Google Scholar
• Allede CC, Allende JE. Purification and substrate specificity of arginyl-ribonucelic acid synthetase from rat liver. J Biochem Chem. 1964; : 1102–6.
   Google Scholar
• Akaogi J, Barker T, Kuroda Y, . Role of non-protein amino acid L-canavanine in autoimmunity. Autoimmun Rev. 2006; 5:429–35.
   PubMed Web of Science ®Google Scholar
• Rosenthal GA. The biological effects and mode of action of L-canavanine, a structural analogue of L-arginine. Quart Rev Biol. ; 52:155–78.
   PubMed Web of Science ®Google Scholar
• Rodgers KJ, Shiozawa N. Misincorporation of amino acid analogues into proteins by biosynthesis. Int J Biochem Cell Bio. 2008; 40:1452–66.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain: importance for CNS drug discovery and development. Pharm Res. 2007; 24:1745–58.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res. 1998; 23:635–44.
   PubMed Web of Science ®Google Scholar
• Hawkins RA, O'Kane RL, Simpson IA, . Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr. 2006; 136:S218–26.
   PubMed Web of Science ®Google Scholar
• O'Kane RL, Vina JR, Simpson I, . Na+-dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal. Am J Physiol Endocrinol Metab. 2004; 287:622–9.
   PubMed Web of Science ®Google Scholar
• Liu X, Rush T, Jasmine Z, Lobner D. Beta-N-methylamino-Lalanine induces oxidative stress and glutamate release through action on system Xc-. Experimental Neurol. 2009; : –. doi:10.1016/j.expneurol.2009.04.002.
   Web of Science ®Google Scholar
• Duncan MW, Villacreses NE, Pearson PG, . 2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. J Pharmacol Exp Ther. 1991; 258:27–35.
   PubMed Web of Science ®Google Scholar
• Smith QR, Nagura H, Takada Y, Duncan MW. Facilitated transport of the neurotoxin, β-N-methylamino-L-alanine, across the blood-brain barrier. J Neurochem. 1992; 58:1330–7.
   PubMed Web of Science ®Google Scholar
• Chase LA, Peterson NL, Koerner JF. The lathyrus toxin, beta-N-oxalyl-L-alpha,beta-diaminopropionic acid (ODAP), and homocysteic acid sensitize CA1 pyramidal neurons to cystine and L-2-amino-6-phosphonohexanoic acid. Toxicol Appl Pharmacol. 2007; 219:1–9.
   PubMed Web of Science ®Google Scholar
• Zhou X, Papapetropoulos S, Zhai RG. L-BMAA induces neurodegeneration in Drosophila. American Academy of Neurology annual meeting. Neurology. 2008; 70Suppl 1:33–.
   Google Scholar
• Wolfersberger MG. Amino acid transport in insects. Ann Rev Entomol. 2000; 45:111–20.
   PubMed Web of Science ®Google Scholar
• Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in ALS. Ann Neurol. 1987; 22:575–9.
   PubMed Web of Science ®Google Scholar
• Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in ALS. Ann Neurol. 1988; 24:446–9.
   PubMed Web of Science ®Google Scholar
• Plaitakis A, Smith J, Mandeli J, . Pilot trial of branched-chain aminoacids in ALS. Lancet. 1988; 1:1015–8.
   PubMed Web of Science ®Google Scholar
• Plaitakis A, Constantakakis E. Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-ascetyl-aspartylglutamate in ALS. Brain Res Bull. 1993; 30:381–6.
   PubMed Web of Science ®Google Scholar
• Testa D, Caraceni T, Fetoni V. Branched-chain amino acids in the treatment of ALS. J Neurol. 1989; 236:445–7.
   PubMed Web of Science ®Google Scholar
• Testa D, Caraceni T, Fetoni V, . Chronic treatment with L-threonine in ALS: a pilot study. Clin Neurol Neurosurg. 1992; 94:7–9.
   PubMed Web of Science ®Google Scholar
• Blin O, Pouget J, Aubrespy G, . A double-blind placebo-controlled trial of L-threonine in ALS. J Neurol. 1992; 239:79–81.
   PubMed Web of Science ®Google Scholar
• Italian ALS Study Group. Branched-chain amino acids and ALS: a treatment failure?. Neurology. 1993; 4:2466–70.
   Google Scholar
• Tandan R, Bromberg MB, Forshew D, . A controlled trial of amino acid therapy in ALS. Neurology. 1996; 47:1220–6.
   PubMed Web of Science ®Google Scholar
• Gibberd FB, Billimoria JD, Page NG, Retsas S. Heredopathia atactica polyneuritiformis (Refsum's disease) treated by diet and plasma exchange. Lancet. 1979; 1:575–8.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with intial penicillamine therapy. Arch Neurol. 1987; 44:490–3.
   PubMed Web of Science ®Google Scholar
• Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum's disease. J Neurol Neurosurg Psychiat. 1991; 54:614–7.
   PubMed Web of Science ®Google Scholar
• Veen C, van den Hamer CJ, de Leeuw PW. Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamine. J Intern Med. 1991; 229:549–52.
   PubMed Web of Science ®Google Scholar
• Lang CJ, Rabas-Kolominsky P, Engelhardt A, Kobras G, Konig HJ. Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol. 1993; 50:1007–8.
   PubMedGoogle Scholar
• Reichel A, Begley DJ, Ermisch A. Arginine vasopressin reduces the blood-brain transfer of L-tyrosine and L-valine: further evidence of the effect of the peptide on the L-system transporter of the blood-brain barrier. Brain Res. 1996; 713:232–9.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Li JY, Chu C, . Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. Biochim Biophys Acta. 2005; 1715:104–10.
   PubMed Web of Science ®Google Scholar
• Killian DM, Hermeling S, Chikhale PJ. Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulphide-based brain drug delivery. Drug Deliv. 2007; 14:25–31.
   PubMed Web of Science ®Google Scholar